Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial | Zendy

José Luís Blanco | Zendy; Jhon Rojas | Zendy; Roger Paredes | Zendy; Eugènia Negredo | Zendy; Josep Mallolas | Zendy; María Casadellà | Zendy; Bonaventura Clotet | Zendy; José M. Gatell | Zendy; Elisa de Lazzari | Zendy; Estebán Martínez | Zendy; Alexy Inciarte | Zendy; Montserrat Laguno | Zendy; Marı́a Martı́nez-Rebollar | Zendy; Berta Torres | Zendy; Montserrat Loncà | Zendy; Amparo Tricas | Zendy; Ana Belén Rodríguez | Zendy; Pilar Callau | Zendy; Montserrat Plana | Zendy; Alberto Crespo | Zendy; S Vicente Sánchez | Zendy; Xavier Carné | Zendy; José Antonio Martínez | Zendy; Francesc Vidal | Zendy

Open Access

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

Author(s) -

José Luís Blanco,

Jhon Rojas,

Roger Paredes,

Eugènia Negredo,

Josep Mallolas,

María Casadellà,

Bonaventura Clotet,

José M. Gatell,

Elisa de Lazzari,

Estebán Martínez,

Alexy Inciarte,

Montserrat Laguno,

Marı́a Martı́nez-Rebollar,

Berta Torres,

Montserrat Loncà,

Amparo Tricas,

Ana Belén Rodríguez,

Pilar Callau,

Montserrat Plana,

Alberto Crespo,

S Vicente Sánchez,

Xavier Carné,

José Antonio Martínez,

Francesc Vidal

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky093

Subject(s) - dolutegravir , medicine , randomized controlled trial , lamivudine , clinical trial , maintenance therapy , pharmacology , virology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , chemotherapy , virus , hepatitis b virus

No controlled comparisons between dolutegravir/lamivudine or dolutegravir maintenance therapy have been done. We hypothesized that these options would have similar efficacy to triple ART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research